MOTS-C RESEARCH PEPTIDE

Metabolism in cells and mice. The team that identified MOTS-c in 2015 found skeletal muscle to be its apparent main target. Their cell experiments showed it blocking the folate pathway and the purine synthesis that depends on it, so that the intermediate AICAR builds up and switches on AMPK, a cellular energy sensor. In mice, they reported that it prevented the insulin resistance that develops with age or on a high-fat diet.¹ A 2018 follow-up in cultured cells found that glucose restriction sent MOTS-c into the nucleus, by an AMPK-dependent route, where it acted on genes with antioxidant response elements and interacted with the transcription factor NRF2.²

Physical capacity and exercise. A 2021 paper reported higher physical performance in young, middle-aged and old mice treated with MOTS-c. It also sampled 10 sedentary young men during ergometer exercise: their own muscle MOTS-c was 11.9-fold higher after exercise, and circulating levels rose about 1.6-fold during it.³ That describes the endogenous peptide, not the effect of giving it.

A gene variant. An mtDNA variant seen in North-East Asian populations turns residue 14 from lysine into glutamine (K14Q). Pooling three cohorts (27,527 people), a meta-analysis tied the variant to more type 2 diabetes among male carriers, with no such association in women. In high-fat-fed male mice, the K14Q peptide did not reproduce the glucose-tolerance change seen with the standard sequence.⁴

Clinical trials. No controlled trial giving MOTS-c to people has yet published clinical outcomes. A registered phase 2a study, NCT07505745, is comparing it with placebo in adults with prediabetes; recruitment opened in February 2026 and no results are posted.⁵ Many foundational papers share authors, some declaring commercial interests, so independent replication is thin.^2,3 The MOTS-c research overview covers each study, and peptides and the WADA Prohibited List explains its anti-doping classification.

Australia's June 2026 Poisons Standard (F2026L00633) does not name MOTS-c.⁶ No MOTS-c medicine is approved, and the research-grade material sold here is not one. How a product is supplied and presented also shapes its legal position; our guide to Australian research peptide law sets out the framework.

For sport, MOTS-c appears by name in section S4.4.1 of the 2026 WADA Prohibited List, in the group of AMP-activated protein kinase activators that also includes AICAR. The category is non-Specified and banned at all times, in and out of competition.⁷ Sport Integrity Australia, the national anti-doping organisation, names MOTS-C among the unapproved peptides it flags as prohibited in sport, and defines unapproved peptide products as goods not entered on the Australian Register of Therapeutic Goods.⁸

With two methionines and a tryptophan in its sequence, MOTS-c is prone to oxidation, so air, moisture and light all count. Store the vial sealed, dark, dry and frozen; supplier guidance runs from −20 °C for short periods to −80 °C for long-term storage. Warm it to room temperature inside a desiccator before opening so no condensation forms on the powder, then reseal promptly; for methionine- or tryptophan-containing sequences, flushing the headspace with nitrogen or argon is recommended. Solutions keep poorly: split a stock into single-use aliquots, freeze them and do not refreeze a thawed tube. More on storing lyophilised and reconstituted peptides and choosing a diluent for reconstitution.